Plain-English translation of NCT07372352 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a new combination of three medications — , Azacitidine, and — for adults with peripheral T-cell lymphoma that has returned or stopped responding to initial treatment. You would receive these medications together for up to six cycles of treatment, and if your lymphoma shrinks, you would continue with one of the medications alone for up to two years. The study wants to learn how well this treatment works and whether it is safe.
Peripheral T-cell lymphoma is an aggressive type of blood cancer with few good options after the first treatment fails. This trial exists because doctors need better, less toxic treatments for patients in this difficult situation, and this medication combination shows promise for helping more patients achieve remission.
You likely qualify if…
You likely don't qualify if…
You would come to the study center regularly for up to six 21-day treatment cycles. During each cycle, you would take one medication by mouth twice daily, receive injections of another medication on days 1-5, and get an intravenous infusion of the third medication on day 1. After three cycles, doctors will check whether your lymphoma is shrinking using imaging scans. If it is, you'll continue with cycles 4-6, and if you respond well, you'll move into a maintenance phase where you take just one medication by mouth for up to two years. Throughout the study, you'll have regular blood tests and check-ins to monitor how you're doing and watch for side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China